Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Blood (2019) 134 (Supplement_1): 5416.

https://doi.org/10.1182/blood-2019-129464

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Lee Mozessohn, MD, Liying Zhang, PhD, Oreofe O. Odejide, MD MPH, Anna M. Tanasijevic, MPH, Richard Chen, BA, Rena Buckstein, MD FRCPC, Robert J. Soiffer, MD, Jorge J Castillo, MD, Andrew Keezer, BS, Jane Driver, MD MPH, Gregory A. Abel, MDMPH

Blood (2019) 134 (Supplement_1): 68.

https://doi.org/10.1182/blood-2019-124946

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Blood (2019) 134 (Supplement_1): 3012.

https://doi.org/10.1182/blood-2019-123684

Published: 2019

Journal Articles

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Blood (2019) 134 (Supplement_1): 4245.

https://doi.org/10.1182/blood-2019-128949

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

Danielle N. Blunt, BMBS, Liam Smyth, MD FRCPath, Evgenia Gatov, Chenthila Nagamuthu, MPH, Rena Buckstein, MD FRCPC, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2018-99-120313

Published: 2018

Journal Articles

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Lee Mozessohn, MD, Matthew Cheung, MD MS, FRCP, Nicole Mittmann, PhD, Craig C. Earle, MD, Ning Liu, Rena Buckstein, MD FRCPC

Blood (2018) 132 (Supplement 1): 834.

https://doi.org/10.1182/blood-2018-99-110223

Published: 2018

Journal Articles

RNA-Seq Analysis of Clonal Hematopoiesis (CHIP) Blood Leukocytes Shows Dysregulation of Neutrophil / Innate Immunity-Related Genes

Elina K Cook, MSc, Richard N Armstrong, PhD, Eshita Sharma, PhD, Brooke Snetsinger, MSc, Jacqueline Boultwood, PhD, Rena Buckstein, MD FRCPC, Andrea Pellagatti, PhD, Michael J. Rauh, MD PhD

Blood (2018) 132 (Supplement 1): 3843.

https://doi.org/10.1182/blood-2018-99-116128

Published: 2018

Journal Articles

A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia

Simon Stanworth, MD, Sally Killick, MD, Zoe McQuilten, MD, Marina Karakantza, MD, Heather Smethurst, RSCN RGN, Laura Pankhurst, M.Sc, Renate L Hodge, B.Sc, M.Sc, Valerie Hopkins, B.Sc, Helen Thomas, M.Sc, Alison J Deary, M.Sc, Rena Buckstein, MD FRCPC, Jeannie Callum, MD, Yulia Lin, MD FRCPC, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 527.

https://doi.org/10.1182/blood-2018-99-112949

Published: 2018

Journal Articles

Forty Percent of MDS Patients Wish They Received Red Blood Cell Transfusions at Higher Hemoglobin Thresholds Than They Currently Are: A Multinational Transfusion Audit

Rena Buckstein, MD FRCPC, Rebecca Starkman, Yulia Lin, MD FRCPC, Simon J. Stanworth, MD, David Bowen, MD PhD, Lea Harrison, Sophie Wintrich, Jeannie Callum, MD

Blood (2018) 132 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2018-99-110560

Published: 2018

Journal Articles

Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study

Blood (2018) 132 (Supplement 1): 4850.

https://doi.org/10.1182/blood-2018-99-114327

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid

Abi Vijenthira, MD, Devyani Premkumar, Richard A. Wells, MD DPhil, Jeannie Callum, MD, Yulia Lin, MD, Lisa Chodirker, MD, Martha Lenis, Alexandre Mamedov, Rena Buckstein, MD FRCPC

Blood (2017) 130 (Supplement 1): 1691.

https://doi.org/10.1182/blood.V130.Suppl_1.1691.1691

Published: 2017

Journal Articles

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, MD MS, Megan Othus, PhD, Alan F. List, MD, Olatoyosi Odenike, MD, Richard M. Stone, MD, Steven D. Gore, MD, Mark R Litzow, MD, Rena Buckstein, MD FRCPC, Min Fang, MD PhD, Diane Roulston, PhD, Clara D. Bloomfield, MD, Yanming Zhang, MD, Mario R. Velasco, MD, Rakesh Gaur, MD MPH, Ehab Atallah, MD, Eyal C. Attar, MD, Frederick R Appelbaum, MD, Harry P. Erba, MD PhD

Blood (2015) 126 (23): 908.

https://doi.org/10.1182/blood.V126.23.908.908

Published: 2015

Journal Articles

Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Ambica Parmar, MD, Heather A Leitch, MD PhD, Richard A. Wells, MD DPhil, Thomas J. Nevill, MD FRCPC, Nancy Y Zhu, MDFRCPC, Karen W.L. Yee, MD, Brian Leber, MD, Mitchell Sabloff, MDM, Eve St-Hilaire, MD, Rajat Kumar, MD, Michelle Geddes, MD FRCPC, John Storring, MD, Andrea Kew, MD, April Shamy, MDM, Mohamed Elemary, MD MSc,PhD, Martha Lenis, Alex Mamedov, Rena Buckstein, MD FRCPC

Blood (2015) 126 (23): 1701.

https://doi.org/10.1182/blood.V126.23.1701.1701

Published: 2015

Journal Articles

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Andrew Aw, MD FRCPC, Lee Mozessohn, MD FRCPC, Isabelle Bence-Bruckler, MD FRCPC, Rena Buckstein, MD FRCPC, Matthew Cheung, MD SM, FRCPC

Blood (2015) 126 (23): 5606.

https://doi.org/10.1182/blood.V126.23.5606.5606

Published: 2015

Journal Articles

Prophylactic Rh and Kell Antigen Matching Significantly Decreases Rates of Alloimmunization in Transfusion Dependent MDS Patients

Aliza Saskin, Yulia Lin, MD, Richard A. Wells, MD DPhil, Martha Lenis, Alex Mamedov, Jeannie Callum, MD, Rena Buckstein, MD FRCPC

Blood (2014) 124 (21): 4297.

https://doi.org/10.1182/blood.V124.21.4297.4297

Published: 2014

NARROW

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Prognostic Value of Disease Risk Score Versus Gait Speed in Older Adults with Lymphoma

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

RNA-Seq Analysis of Clonal Hematopoiesis (CHIP) Blood Leukocytes Shows Dysregulation of Neutrophil / Innate Immunity-Related Genes

A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia

Forty Percent of MDS Patients Wish They Received Red Blood Cell Transfusions at Higher Hemoglobin Thresholds Than They Currently Are: A Multinational Transfusion Audit

Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Combined Modality Therapy in the Upfront Treatment of Patients with Primary Central Nervous System Lymphoma: A Systematic Review

Prophylactic Rh and Kell Antigen Matching Significantly Decreases Rates of Alloimmunization in Transfusion Dependent MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only